Related Experiment Video

Updated: Jul 13, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Uric acid reduction: a new paradigm in the management of cardiovascular risk?

Jesse Dawson1, Terry Quinn, Matthew Walters

  • 1Division of Cardiovascular and Medical Sciences, University of Glasgow, Western Infirmary Hospital, Dumbarton Road, Glasgow, G11 6NT, UK. j.dawson@clinmed.gla.ac.uk

Current Medicinal Chemistry
|July 14, 2007
PubMed

Insights

High uric acid levels are linked to cardiovascular disease. Lowering uric acid may reduce cardiovascular risk, offering a novel preventative strategy.

Area of Science:

  • Biochemistry
  • Cardiology
  • Nephrology

Background:

  • Uric acid is the final product of purine metabolism.
  • Hyperuricemia is associated with gout, urolithiasis, and potentially cardiovascular morbidity and mortality.
  • Emerging evidence suggests a link between elevated uric acid and increased cardiovascular risk.

Purpose of the Study:

  • To review epidemiological data on uric acid and cardiovascular disease.
  • To discuss methods for lowering uric acid levels.
  • To evaluate clinical trial data supporting uric acid reduction for cardiovascular disease prevention.

Main Methods:

  • Review of epidemiological studies linking uric acid levels to cardiovascular outcomes.
  • Analysis of pharmacological interventions targeting uric acid reduction (e.g., losartan, atorvastatin, fenofibrate).
  • Examination of studies on xanthine oxidase inhibition and its effects on cardiovascular and endothelial function.

Main Results:

  • Epidemiological data suggest a correlation between higher uric acid levels and increased cardiovascular risk.
  • Certain medications (losartan, atorvastatin, fenofibrate) may attenuate cardiovascular risk through uric acid reduction.
  • Xanthine oxidase inhibition has shown potential in improving cardiovascular and endothelial function in small studies.

Conclusions:

  • Uric acid reduction is a potential novel strategy for cardiovascular disease prevention.
  • Further clinical trials are needed to establish a direct causal role and optimize therapeutic approaches.
  • Lowering uric acid may offer a new avenue for managing cardiovascular risk.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...